Pharmacyclics
Ada Braun is a seasoned professional in the pharmaceutical industry, currently serving as the Regulatory Affairs Therapeutic Area Head and Executive Director of Regulatory Affairs at Pharmacyclics, an AbbVie Company, since February 2017. Prior to this role, Ada held the position of SVP Clinical Development at AROG Pharmaceuticals, Inc. from October 2015 to August 2016 and was the Chief Medical Officer at Biothera from March 2014 to July 2015. Ada has also contributed to Amgen as an Executive Medical Director in Hematology/Oncology and as a Clinical Research Medical Director from November 2006 to February 2014. Academically, Ada holds a PhD in Oncology/Pharmacology from Vanderbilt University and an MD from Paris-Sud University (Paris XI), along with additional training from UCLA Anderson School of Management.
This person is not in any teams
Pharmacyclics
1 followers
Pharmacyclics is committed to the development and commercialization of novel therapies intended to improve the quality and duration of life and to resolve serious unmet medical needs for cancer patients. Pharmacyclics is a wholly-owned subsidiary of AbbVie (NYSE:ABBV), a global, research-based biopharmaceutical company. Oncology is a key therapeutic area for AbbVie, with a portfolio consisting of three marketed products and a pipeline containing multiple promising new molecules that are being studied in more than 200 clinical trials for over 20 different types of cancer. More than 1,200 Pharmacyclics and AbbVie research scientists, clinicians, marketing, operations and corporate professionals work in the San Francisco Bay Area. They combine their expertise in immuno-oncology, stem cells, and cell-signaling with their knowledge of bispecific antibodies, antibody-drug conjugates (ADCs), and covalent-inhibitor technologies to discover and develop novel cancer treatments. Together, we are striving to outsmart cancer.